Publication of supplement to prospectus
Oncology Venture Sweden AB (”Oncology Venture”) hereby publish a supplement to the prospectus due to the press release with the headline “Oncology Venture will execute license to multi TKI phase 3 compound” that the company published on January 15th, 2018, which was published after the approval of the company’s prospectus by the Swedish Financial Supervisory Authority prior to Oncology Venture’s rights issue with subscription period on January 11th – January 25th, 2018. The supplement to the prospectus is available on the company’s (www.oncologyventure.com), Sedermera Fondkommission’s (www.sedermera.se) and AktieTorget’s (www.aktietorget.se) respective websites.
Sedermera Fondkommission is the financial advisor to Oncology Venture in connection with the rights issue.
For questions concerning the rights issue, please contact:
Telephone: +46 (0) 40-615 14 10
For further information, please contact
|Ulla Hald Buhl, COO and Chief IR & CommunicationsMobile: +45 2170 1049E-mail: email@example.com||Or||Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: firstname.lastname@example.org|
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP® – in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates. OV-SPV 2 is a Danish company that shall test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor. Oncology Venture currently holds 92 percent of the shares in 2X Oncology Inc. and 40 percent of the shares in OV-SPV 2.